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AbstrACt
Objectives Degenerative cervical myelopathy (DCM) 
presents insidiously, making initial diagnosis challenging. 
Surgery has been shown to prevent further disability but 
existing spinal cord damage may be permanent. Delays 
in surgery lead to increased disability and reduced 
postoperative improvements. Therefore, rapid surgical 
assessment is key to improving patient outcomes. 
Unfortunately, diagnosis of DCM in primary care is often 
delayed. This study aimed to characterise patients with 
DCM route to diagnosis and surgical assessment as well 
as to plot disease progression over time.
Design Retrospective, observational cohort study.
setting Single, tertiary centre using additional clinical 
records from primary and secondary care centres.
Participants One year of cervical MRI scans conducted 
at a tertiary neurosciences centre (n=1123) were 
screened for cervical cord compression, a corresponding 
clinical diagnosis of myelopathy and sufficient clinical 
documentation to plot a route to diagnosis (n=43).
Primary outcome measures Time to diagnosis 
from symptom onset, route to diagnosis and disease 
progression were the primary outcome measures in 
this study. Disease severity was approximated using a 
prospectively validated method for inferring modified 
Japanese Orthopaedic Association (i-mJOA) functional 
scoring from clinical documentation.
results Patients received a referral to secondary 
care 6.4±7.7 months after symptom onset. Cervical 
MRI scanning and neurosurgical review occurred 
12.5±13.0 and 15.8±13.5 months after symptom onset, 
respectively. i-mJOA was 16.0±1.7 at primary care 
assessment and 14.8±2.5 at surgical assessment. 
61.0% of patients were offered operations. For those who 
received surgery, time between onset and surgery was 
22.1±13.2 months.
Conclusions Route to surgical assessment was 
heterogeneous and lengthy. Some patients deteriorated 
during this period. This study highlights the need for a 
streamlined pathway by which patients with cervical cord 
compression can receive timely assessment and treatment 
by a specialist. This would improve outcomes for patients 
using existing treatments.
IntrODuCtIOn 
Degenerative cervical myelopathy (DCM) 
is an umbrella term for compression of the 
cervical spinal cord due to degenerative 
pathologies, such as osteophyte formation, 
intervertebral disc protrusion and ligament 
hypertrophy or ossification.1 The estimated 
minimum incidence and prevalence of DCMs 
are 41 and 605 per 1 000 000, respectively, in 
North America.1 However, this is likely to be 
an underestimate as DCM often goes undi-
agnosed and epidemiology frequently relies 
on operative incidence.1 In a recent study 
of 183 randomly selected adults aged 40–80, 
59% had radiological evidence of cervical 
cord compression and 1% as yet undiag-
nosed DCM. The evolution of incidental 
cord compression is unclear, but in the only 
study of its kind, Bednarik et al demonstrated 
23% went onto develop DCM in a series of 
199 patients.2 These findings would suggest 
that DCM is far more common than currently 
demonstrated.
DCM causes progressive neurological 
dysfunction leading to significant disability 
and reduction in quality of life for patients.3 
Symptoms include limb spasticity, numb 
and clumsy hands, sphincter dysfunction, 
neck and limb pain, imbalance, and limb 
weakness leading to falls.4 These symptoms 
often arise and progress insidiously in either 
strengths and limitations of this study
 ► This is the largest study to characterise patient with 
degenerative cervical myelopathy flow and the first 
to do so within the UK healthcare system.
 ► Centralised, electronic case notes permitted accu-
rate construction of patient flow pathways through-
out the healthcare system.
 ► Sparse clinical records lead to the exclusion of some 
cases that would otherwise have been suitable and 
thus decreased sample size.
 ► This study was conducted in a single  centre, 
and thus, further work is required to generalise 
conclusions.
 ► True modified Japanese Orthopaedic Association 
(mJOA) scores were not available, and thus, infer-
ring mJOA was developed to retrospectively assess 
disease severity from case notes.
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a stepwise or continuous manner.5 The rate of progres-
sion varies between individuals and cannot currently be 
predicted.
A diagnosis of DCM requires congruent symptoms, 
clinical and MRI findings, typically evidence of spinal 
cord compression.6 Surgery is the only evidence-based 
treatment for DCM and has been shown to halt disease 
progression and afford some improvement across a 
number of domains.5 7 8 However, few patients make 
a complete recovery. This is due to the limited regen-
erative capacity of the spinal cord; as a result existing 
damage is often permanent and leads to lifelong disabil-
ities. A recent study has demonstrated that patients with 
DCM have among the lowest 36-Item Short Form Survey 
(SF-36)  scores of chronic diseases.9 Therefore, improving 
functional recovery in DCM is a major unmet clinical 
need.
Recent international guidelines advise that all patients 
with DCM should be assessed by a specialist service and 
surgery offered for moderate to severe disease, as well as 
any progressive disease.10
Prognostic factors for postoperative functional 
improvement have been extensively studied. The main 
predictor of outcome is presurgical morbidity. Detecting 
progressive disease and early intervention is therefore 
important. Moreover, longer preoperative symptom 
duration is associated with poorer postoperative 
improvement.11–16 In the largest cohort study of patients 
with DCM, surgery within 6 months of symptom onset 
offered the best chance of recovery. In this context, 
rapid referral to a spinal surgeon followed by prompt 
surgical intervention when appropriate is key to mini-
mising disability.
Unfortunately, patients with DCM report significant 
delays in diagnosis.17 This is corroborated in the study 
of Behrbalk et al18 who found that most patients in Israel 
wait more than 2 years for a diagnosis.18 If this could be 
overcome, outcomes would improve based on existing 
treatment strategies. While the delay in diagnosis is 
becoming better recognised, where and why the delays 
occur remain unclear.
Healthcare system research aims to characterise patient 
pathways, to identify the ‘where’ and ‘why’ of delays, to 
allow targeted logistical interventions. This process has 
been successful in cancer presentation and manage-
ment,19–22 informing clinician-based and public poli-
cy-based initiatives to improve cancer care.
Our objectives, therefore, were to characterise the 
patient with DCM pathways within the UK healthcare 
system in order to support targeted interventions aimed 
at accelerating diagnosis and management. This is the 
first study of its kind in the field of DCM.
MethODs
study description
Retrospective, observational cohort study.
Cohort description
The radiological reports of all cervical spine MRI scans 
conducted over 1 year in a single, tertiary neurosciences 
centre were screened for descriptions of cervical spinal 
cord compression. The centre serves an estimated popu-
lation of 5.9 million, although a considerable proportion 
of spinal patients are initially seen and are imaged, and 
may be managed in secondary care centres.22 The clinical 
records corresponding to these scans were examined and 
cross-matched against inclusion criteria: non-traumatic 
cord compression due to spinal degeneration, a clinical 
diagnosis of DCM and adequate clinical documentation 
to characterise the referral pathway. Cases that met these 
criteria formed the cohort for this study (figure 1).
Peripheral hospitals in our region use different elec-
tronic and paper record keeping systems from one 
another and from this tertiary centre. Therefore, this 
study only included patients imaged in our centre, as this 
permitted full access to clinical documentation required 
to accurately document patient pathways.
Patient and public involvement
This study was developed in response to patient reports 
of frequent and long delays in their diagnosis and 
management. These reports came from the community 
of  myelopathy. org, an international DCM charity and 
were reconfirmed as a priority research area during a 
patient and public involvement day at the University of 
Cambridge. Some of these interviews were featured in 
a video documentary for Cambridge TV. While patients 
drove the theme for the study through their testimonials, 
they were not involved in the exact design of the study, 
which was informed by local referral pathways and liter-
ature on DCM. Once published, this study will be shared 
through  myelopathy. org to make its findings widely avail-
able to patients with DCM and carers.
Data collection
All relevant clinical records (assessments, correspon-
dences, inpatient documentation) were examined for 
the cohort cases. Demographic data were collected: age 
Figure 1 Flow diagram depicting cohort formation 
methodology. DCM, degenerative cervical myelopathy.
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at time of onset, sex, relevant commodities, previous 
episodes of DCM and previous cervical surgery.
retrospective assessment of disease severity
The modified Japanese Orthopaedic Association (mJOA) 
is a common and well-validated assessment of disability 
in DCM.10 23 A retrospective method for assessment of 
the patient’s mJOA score was developed (table 1) and 
prospectively validated (n=13) using a kappa statistic. 
This was termed the inferred mJOA (i-mJOA). i-mJOA 
was developed as a research tool for this study to allow 
retrospective assessment of change in DCM disability, 
as grading tools are not routinely employed in clinical 
consultations. It was not specifically developed for wider 
usage, which would require thorough external validation 
prior to application.
 i-mJOA development methodology
1. A translation of mJOA into i-mJOA was designed based 
on commonly reported clinical details in patients’ elec-
tronic records (eg, ‘walking aid’ vs ‘no walking aid’ im-
balance, or 0–5/5 power grading). This translation is 
presented in table 1.
2. The electronic records of 13 patients assessed by a spi-
nal clinic in our centre were collected. These were pa-
tients outside of the study range dates and thus were 
not included in our study. mJOA assessments were 
made during their clinical consultations, and there-
fore, a formal mJOA score was available.
3. These records were anonymised and the mJOA ques-
tionnaire results were removed.
4. The mJOA to i-mJOA translation was applied to these 
patient records.
5. True mJOA and i-mJOA scores were then statistically 
analysed using the kappa statistic. The results are pre-
sented below.
The i-mJOA and mJOA had good agreement (0.73), 
specifically upper limb (0.66), lower limb (0.75), sensory 
(0.32), sphincter (0.29) and total mJOA (0.73). Average 
differences between i-mJOA and mJOA ±SD were: 
upper limb (0.13±0.92), lower limb (0.13±0.92), sensory 
(−0.4±0.74), sphincter (0.27±0.70) and total mJOA 
(0.13±1.51).
This experimental tool was applied to assess the disease 
severity of our cohort. If no features for a subcategory of 
i-mJOA were documented, the category was assigned the 
highest score. i-mJOA subcategory scores were assumed 
to stay constant over time unless specifically mentioned 
to have improved or deteriorated. If the criteria were 
met for more than one score within a subcategory, the 
lower score was assigned. i-mJOA scores are reported as 
mean±SD.
Analysis
Statistical analysis was carried out using SPSS V.22. Bivar-
iate analysis was conducted between variables using Pear-
son’s and Spearman’s correlations depending on the 
variable types involved. Wilcoxon signed-rank test was 
used to calculate significant changes in i-mJOA from 
primary care referral to surgical assessment. As cases were 
selected on the basis of having sufficient documentation, 
there were no missing data.
results
study demographics
A total of 1123 total scans were screened, resulting in a 
final cohort of 43 DCM cases (figure 1). The vast majority 
of these scans were of unique patients, although rarely 
patients were reimaged. The average age at time of 
symptom onset was 61.4±13.9 years and the majority of 
patients (28, 65%) were male. Of the 43 cases, 22 (51%) 
experienced previous myelopathy and the other 21 (49%) 
were presenting for the first time.
heterogeneity in primary referrals of patients with DCM points 
to the lack of a unified pathway
Thirty-three primary referrals were accessible to review. 
The majority of these were made by a general practi-
tioner (28, 85%) and less frequently by a physiotherapist 
(3, 9%) or other peripheral hospital (2, 6%). Half of all 
DCM cases were referred directly to a spine surgeon (22, 
51%) while the other were seen by other specialties first 
(21, 49%), including neurology (n=16), orthopaedics 
(n=2), pain management (n=1), rheumatology (n=1) and 
geriatric medicine (n=1). Almost all cases (42, 98%) were 
ultimately reviewed by a spinal surgeon. Referral path-
ways are displayed separating new myelopathy cases from 
recurrent cases (figure 2).
Patients with DCM encounter significant delays from the onset 
of symptoms to the time of primary referral
Symptom onset was defined as the point at which the 
patient first experienced symptoms. For example, if a 
primary referral stated the patient had been experi-
encing numbness in his fingers for 4 months. The onset 
of symptoms was defined as 4 months prior to the date 
of this referral. The times between symptom onset and 
primary referral for new and recurrent cases of DCM 
were 8.3±10.1 and 6.4±4.2 months, respectively. Seven-
ty-six per cent (16/21) of new cases and 24% (5/22) of 
recurrent cases of DCM were referred to an alternative 
specialist for secondary assessment rather than directly 
to a spine surgeon. The times between primary referral 
and secondary assessment for new and recurrent cases of 
DCM were 1.5±0.8 and 1.9±1.2 months, respectively.
secondary referral to spine surgery is consistently delayed 
and does not take patient characteristics into account
Following secondary assessment, all patients apart from 
one were then referred on to see a spine surgeon. The 
one non-referred patient had a complex neurological 
and social background with mild myelopathy and was 
deemed better managed with regular neurology follow-up 
than consideration of spinal surgery. The times between 
secondary assessment and surgical assessment for new 
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and recurrent cases of DCM were 5.1±4.0 and 5.5±2.2 
months, respectively. No clinical feature, patient demo-
graphic factor or specialty of secondary assessment was 
associated with a significantly different speed of referral 
to spinal surgeon review.
A minority of new patients with DCM are directly referred to 
spine surgery
Twenty-four per cent (5/21) of new cases and 77% 
(17/22) of recurrent cases were referred from primary 
assessment directly to a spine surgeon. The times between 
primary assessment and surgical assessment for these new 
and recurrent cases of DCM were 3.7±4.1 and 0.9±2.2 
months, respectively. The only factor associated with 
direct referral to a spinal surgeon was previous DCM 
(p<0.001). The overall times between symptom onset and 
surgical assessment for new and recurrent cases of DCM 
were 17.7±16.0 and 9.5±9.0 months, respectively. Of the 
new cases of DCM, 45% (9/20) received an operation, 
35% (7/20) received a follow-up appointment with a 
spine surgeon and 20% (4/20) were discharged. Of the 
recurrent cases of DCM, 50% (11/22) received an opera-
tion, 23% (5/22) received a follow-up appointment with 
a spine surgeon and 27% (6/22) were discharged.
significant delays in MrI scans relative to symptom onset 
may contribute to delayed diagnosis of DCM
The observed cohort was formed on the basis of diag-
nostic cervical MRI scans, demonstrating spinal cord 
compression. Relative to symptom onset, the scan was 
performed 17.7±15.6 and 9.5±8.7 months after symptom-
atic onset for new and recurrent cases of DCM, respec-
tively. This scan was performed at 1.4±4.7 and 3.3±4.2 
months after secondary assessment for new and recurrent 
cases of DCM, respectively. Relative to surgical review, 
it was performed at 2.3±0.7 months before and 0.5±1.2 
months after surgical assessment for new and recurrent 
cases of DCM, respectively. Thus, in general, imaging of 
new DCM cases was conducted prior to reaching a spinal 
surgeon, whereas recurrent cases were imaged after initial 
surgical consultation.
Patients with DCM continue to deteriorate along the pathway 
from referral to treatment
Between the earliest recorded assessment (primary or 
secondary) and surgical assessment, the following deteri-
orations in i-mJOA scores were observed (figure 3). Fifty-
nine per cent of patients deteriorated, 24% remained 
stable and 17% showed improvement, presumably due 
to symptom fluctuation or resolution of disc herniation. 
The total i-mJOA change for individual patients ranged 
from +4 to −6 points. On average, patients who deterio-
rated displayed a reduction of 2.3±1.8 i-mJOA points.
DIsCussIOn
The pathway from symptom onset to diagnosis and 
surgical assessment is complex and highly heterogeneous 
for patients with DCM. They face long delays before a 
diagnosis and further delays before surgical assessment. 
During this time, most experience a progression in symp-
toms. However, DCM symptoms are by at large, not revers-
ible. The observed deterioration is, therefore, likely to 
translate into increased long-term disability and lead to 
lower quality of life.
A diagnosis of DCM is made before reaching a spinal surgeon
Patients with DCM principally enter the healthcare system 
via primary care. They are then referred via another 
specialty for assessment and imaging, typically neurology, 
before reaching a spinal surgeon. This contrasts the study 
by Behrbalk et al, the only other study to consider the 
DCM healthcare system, which found most patients were 
initially assessed by orthopaedics.18 A potential expla-
nation is that patients may self-refer to orthopaedics in 
Israel but require a formal referral to neurology or neuro-
surgery. Regardless, both studies have demonstrated that 
Figure 2 Patient referral pathways from symptom onset for recurrent cases of DCM (left) and new cases of DCM (right). Times 
are given in the format: average months±SD (number of cases). Dashed lines represent total time durations, not a specific 
patient pathway. DCM, degenerative cervical myelopathy.












pen: first published as 10.1136/bm





7Hilton B, et al. BMJ Open 2019;9:e027000. doi:10.1136/bmjopen-2018-027000
Open access
the diagnosis of new-onset DCM is made outside of spinal 
surgery.
This finding is significant as DCM treatment and 
research is largely led by spinal surgeons. In order to 
accelerate diagnosis and improve outcomes based on 
existing treatment paradigms, greater clarity of the inter-
action between other specialties and patients with DCM 
is critical.
Patients with DCM wait months for a diagnosis and years for 
treatment
Delays in patient pathways were noted in all components 
of the system. The greatest delay appears to exist between 
disease onset and primary referral to secondary care. This 
is consistent with Behrbalk et al and patient experience.18
The cause for this delay is likely to be multifactorial. 
Potential factors include late presentation by patients, 
subtle or non-specific symptoms and examination find-
ings,24 25 misdiagnoses and a lack of awareness of DCM. 
Future studies are required to determine the exact 
reasons for prereferral delays in order to develop targeted 
interventions.
Minimising delays of treatment is especially important 
in DCM, because length of symptoms and disease severity 
are the two most important factors that determine 
response to surgery of patients with DCM.13–15 More-
over, shortening the times until patients are seen by a 
myelopathy specialist is likely to be the single most effec-
tive strategy of improving patient outcomes.
the lack of a unified pathway is likely to contribute to delays 
in treatment
The majority of new cases (76%) were not directly 
referred to a spine surgeon but instead were reviewed 
by neurologists, orthopaedics, pain specialists, rheuma-
tologists and geriatricians. The specialty performing the 
secondary assessment did not influence referral speed 
from secondary care to spinal surgery. These findings 
corroborate that there is no streamlined pathway for 
surgical assessment of a patient with DCM.
At the early stages, symptoms are often subtle and often 
missed by non-specialists. However, even asymptomatic 
patients with MRI-proven cervical spinal cord compres-
sion run a considerable risk of developing myelopathy. 
A recent study found that 59% of asymptomatic individ-
uals over 40 had cervical cord compression on MRI.26 
A further study observed that 13% of non-myelopathic 
individuals with cervical cord compression developed 
myelopathy within a 2-year period.27
Our data indicated that disease severity did not influ-
ence speed of referral to a spine surgeon. This may seem 
counterintuitive but potentially be explained by the broad 
range of symptoms associated with myelopathy.
Figure 3 i-mJOA scores at each clinical phase of assessment. Mean±SD. i-mJOA, Inferring modified Japanese Orthopaedic 
Association.
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For these reasons, the authors advocate more rapid 
assessment by a specialist service once a patient has 
proven cord compression, especially alongside clinically 
myelopathic features. This is also reflected in the first 
recent international guidelines.10
Patients with DCM continue to deteriorate while they wait for 
treatment
This study found that 59% of patients deteriorated 
between their earliest available assessment and the point 
at which they reached assessment by a spine surgeon. 
The minimum clinically important difference in DCM 
varies by disease severity28 29: 1 point for mild disease 
(mJOA ≥15), 2 points for moderate disease (mJOA 
score of 12–14) and 3 points for severe disease (mJOA 
score <12). In the deteriorating group, all but one patient 
were found to have a mild disease (mJOA ≥15) at initial 
assessment. Within this group, the average deterioration 
was 2.3 i-mJOA points, demonstrating clinically significant 
disease progression. More rapid DCM referral services 
and streamlined pathways to specialist assessment could 
help to prevent this source of potentially non-reversible 
deterioration.
What would the ideal pathway be for assessment and 
management of DCM?
As it stands, these data show new diagnosis and manage-
ment as a two-stage process. Stage 1: patients receive a 
diagnosis of DCM outside of spinal surgery based on 
clinical symptomatology and MRI findings. Stage 2: 
onward referral to spinal surgery and surgery is offered 
if indicated.
While direct referral to spinal surgery on initial clin-
ical suspicion would significantly shorten this process, it 
would likely lead to a number of problems. First, given 
the nature of DCM’s non-specific symptoms, especially 
early on, and the limited access in the UK to MRI imaging 
within primary care, this would lead to many inappro-
priate referrals and place a strain on already stressed 
outpatient spinal services. Second, these inappropriate 
referrals are then being assessed by specialists, who can 
confidently consider DCM, but will not be best placed or 
experienced to consider other differentials. Therefore, 
the exclusion of myelopathy could place delays on other 
diagnoses.
Similar dilemmas have been addressed for many other 
conditions using intermediate pathways. For example, 
in the UK, we have a ‘musculoskeletal’ pathway triaging 
complaints such as lower back pain and joint pain. In 
this pathway, patients are referred to physiotherapy-led 
assessment centres, with access to investigations such as 
MRI and electrophysiology. These centres have access 
to specialist multidisciplinary teams (MDTs), who help 
to decide whether patients can be managed locally or 
referred to specialist services. A recent systematic review 
has shown such triage was concordant with specialists 
68%–96% of the time and reduced referrals to specialist 
clinics by 20%–60%.30
At present, the ‘musculoskeletal’ service is better 
geared to classically ‘orthopaedic’ or ‘rheumatological’ 
conditions and a potential weakness for DCM would be 
neurological mimics. In this study, only 9% of referrals 
came from this musculoskeletal service, with most patients 
being referred to neurology. A more refined assessment 
process will require further research. Building on the 
existing intermediate pathway with closer involvement of 
neurology might be a sensible approach.
For recurrent disease, this study shows that direct access 
to spinal surgery is appropriate. Of the patients referred, 
50% received operations and 23% were kept under 
surveillance. We speculate that these patients’ previous 
DCM diagnosis heightened awareness by patient and 
healthcare practitioner, leading to a greater confidence 
in direct referral to spinal services.
limitations
While this study was conducted in a single neurosciences 
centre, it serves a large regional population, almost a 
tenth of the UK population as a whole.31 Additionally, 
given the UK has a National Health Service that delivers 
care within common structures, the findings in this study 
are likely generalisable throughout at least the UK health 
system.
The epidemiology of DCM is poorly characterised, 
however, it is thought to be a common condition.32 The 
identification of only 43 cases of DCM over 1 year was 
lower than expected. However, the majority of patients 
receiving treatment at this neurosciences centre present 
with external imaging obtained in referring secondary 
centres, which did not facilitate access to full clinical 
records as described in the methodology. Hence, these 
patients were not included in the present cohort. The 
low number, therefore, is likely to reflect the role of the 
neuroradiology department acting as a secondary centre 
serving a more local population.
The retrospective nature of the study leads to the devel-
opment of i-mJOA. While true mJOA would have been 
preferable, the strong kappa statistics and low average 
difference indicate that total i-mJOA does represent a 
reliable proxy and broad-brush method of demonstrating 
disease severity and changes in disease severity over time 
retrospectively.
COnClusIOns
This work demonstrates that patients experience signif-
icant delays in diagnosis and time to surgical review. 
During this time, disease progression occurred and 
patients functionally deteriorated. The best postoperative 
outcomes for patients with DCM are attained with rapid 
surgical review and intervention when appropriate. Our 
findings call for the formation of dedicated streamlined 
pathways to surgical review for patients with spinal cord 
compression on MRI, especially in the context of clin-
ical myelopathy. Further prospective system characterisa-
tion of factors associated with patient flow is needed to 
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introduce specific targeted interventions to improve the 
management of DCM in the UK.
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